“Novo Nordisk heard loud and clear the impact to the 15,000 Australians living with diabetes who depended on FIASP, if FIASP was no longer available on the PBS. We are pleased that patients can continue accessing this treatment on the PBS,” said Cem Ozenc, corporate vice president and general manager of Novo Nordisk Oceania.
Patients win reprieve with Novo Nordisk listing a new form of insulin aspart
September 17, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News -
Sanofi employees contribute over 400 volunteer hours to community and environmental causes
November 6, 2025 - - Latest News -
Neuren posts record royalties as DAYBUE sales surpass US$100 million in third quarter
November 6, 2025 - - Australian Biotech -
US Ambassador warns UK risks losing pharma investment unless it pays more for medicines
November 6, 2025 - - Latest News -
Pfizer to continue legal fight as court rejects bid to block Novo Nordisk’s Metsera takeover bid
November 6, 2025 - - Latest News -
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 - - Latest News
